Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery

• Status: Suspended
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Increasing rates of obesity over the last few decades have led to growing demand for bariatric surgery, which may resulted in decreased comorbidities and improved patient outcomes. Laparoscopic bariatric surgery has several clinical benefits in terms of improved quality of analgesia, reduced pulmonary complications, enhanced recovery of bowel function, less immune suppression, and shortened duration of hospital stay than open laparotomies.

Some investigators reported delayed return of bowel function for approximately two days after laparoscopic bariatric surgery, despite it occurred one day earlier than after open laparotomy. This potentially can lengthen the duration of hospital stay after bariatric procedures. With the impeding cost of health care in the developing countries, safely reducing length of stay is essential.

Other investigators reported early return of bowel movements during the first postoperative day in 65% of patients undergoing laparoscopic gastric bypass surgery due to reduced morphine use with implementation of a multimodal analgesia strategy including ketorolac, and propoxyphene hydrochloride/acetaminophen.

Lidocaine was investigated in several studies for its use in multi-modal management strategies to reduce postoperative pain and opioid use and enhance recovery. A recent Cochrane review including 45 trials demonstrated that systemic administration of lidocaine was associated with reduced pain scores at most of 'early time points' in patients undergoing laparoscopic abdominal surgery (MD -1.14, 95% CI -1.51 to -0.78; low-quality evidence), shorter times to first flatus (MD -5.49 hours, 95% CI -7.97 to -3.00; low-quality evidence) and first bowel movement (MD -6.12 hours, 95% CI -7.36 to -4.89; low-quality evidence), and less risk of paralytic ileus (risk ratio (RR) 0.38, 95% CI 0.15 to 0.99; low-quality evidence). However, no evidence of effect was found for lidocaine on shortening the time to first defecation. This low-quality evidence may be related to the heterogeneity between the studies in respect to the optimal dose, timing and duration of the administration of intravenous lidocaine.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Lidocaine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Obese patients with a body mass index equal or greater than 35 kg/m2.

• American Society of Anesthesiologists (ASA) II-III

• Patients scheduled for laparoscopic bariatric surgery under general anesthesia

Exclusion Criteria:

• History of significant cardiac disease.

• History of significant respiratory disease.

• History of significant hepatic disease.

• History of significant renal diseases.

• History of an atrio-ventricular block grade II to III.

• Long QT syndrome.

• Pre-existing disorder of the gastrointestinal tract.

• Patients with history of alcohol or drug abuse.

• Allergy to amide local anesthetics.

• History of epilepsy.

• Pregnancy.

• Patients receiving cardiovascular medications.

• Patients receiving steroids.

• Patients receiving an opioid analgesic medication within 24 h before the operation.

• Conversion from a laparoscopic to an open laparotomy.